首页> 外国专利> METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION IN THE FORM OF EXTENDED-RELEASE TABLETS CONTAINING PIRFENIDONE AND USE THEREOF IN THE REGRESSION OF CHRONIC RENAL INSUFFICIENCY BREAST CAPSULAR CONTRACTURE AND HEPATIC FIBROSIS IN HUMANS

METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION IN THE FORM OF EXTENDED-RELEASE TABLETS CONTAINING PIRFENIDONE AND USE THEREOF IN THE REGRESSION OF CHRONIC RENAL INSUFFICIENCY BREAST CAPSULAR CONTRACTURE AND HEPATIC FIBROSIS IN HUMANS

机译:制造包含吡非尼酮的可延缓释放片剂形式的药物组合物的方法,并在慢性肾功能不全,男性,男性,男性,男性,男性,男性,男性,女性,男性,女性,男性,女性,男性,女性患者中的应用

摘要

The present invention relates to a process for the preparation of a pharmaceutical composition of the sustained release tablet type comprising 600 milligrams to 2400 milligrams of pyflnidon (PFD) in such a manner that the drug is bioavailable for an extended period of time of 12 hours from its administration will be. In this way, the anti-fibrosis and anti-inflammatory action of the drug pyperidone is optimized. The present invention also relates to the advantages of comparing the different pharmaceutical forms of pypenidone for oral administration and their therapeutic effect in the regression of chronic renal failure due to higher therapeutic efficacy and primary glomerulosclerosis Suggest application; This shows better activity in reducing and / or regressing harmful effects in breast capsular contractures observed after surgical implantation of breast implants in humans and is associated with a significant anti-TNF RTI ID = 0.0 -a and anti-TGF-? 1 action.
机译:本发明涉及一种制备持续释放片剂类型的药物组合物的方法,该药物组合物包含600毫克至2400毫克的吡非尼定(PFD),使得该药物可从12小时的延长时间内被生物利用。它的管理将是。以这种方式,优化了药物哌啶酮的抗纤维化和抗炎作用。本发明还涉及比较口服的哌啶酮的不同药物形式的优点及其在归因于更高的治疗功效和原发性肾小球硬化导致的慢性肾衰竭消退中的治疗作用的优点。这显示出在减轻和/或消退在人类中植入乳房植入物后观察到的对乳房荚膜挛缩的有害作用的更好的活性,并且与显着的抗TNF-α和抗TGF-β有关。 1动作。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号